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observed in the overnight effluent during treatment with theLong-term clinical effects of a peritoneal dialysis fluid with less
new fluid.glucose degradation products.
Conclusions. We conclude that the new fluid with a higherBackground. Glucose degradation products (GDPs) are cy-
pH and less GDPs is safe and easy to use and has no negativetotoxic in vitro and potentially toxic in vivo during peritoneal
effects on either the frequency of peritonitis or peritoneal trans-dialysis (PD). We are presenting the results of a two-year
port characteristics as compared with conventional ones. Ourrandomized clinical trial of a new PD fluid, produced in a
results indicate that the new solution causes less mesothelialtwo-compartment bag and designed to minimize heat-induced
and interstitial damage than conventional ones; that is, it mayglucose degradation while producing a near neutral pH. The
be considered more biocompatible than a number of conven-effects of the new fluid over two years of treatment on mem-
tional PD solutions currently in use.brane transport characteristics, ultrafiltration (UF) capacity,
and effluent markers of peritoneal membrane integrity were
investigated and compared with those obtained during treat-
ment with a standard solution. Conventional fluids for peritoneal dialysis (PD) areDesign. A two-group parallel design with 80 continuous am-
potentially bioincompatible because of their hyperosmo-bulatory peritoneal dialysis patients was used. The patients
lality, low pH, and high lactate and glucose concentra-were randomly assigned to either the new fluid (N 5 40) or
to a conventional one (N 5 40), and were stratified with respect tions [1, 2]. Especially the high glucose concentrations
to age, diabetes, and time on PD. Peritoneal transport charac- in conventional fluids have been incriminated as being
teristics were assessed by the Personal Dialysis Capacity (PDCe) detrimental to the peritoneum, not the least by providingtest at 1, 6, 12, 18, and 24 months after inclusion and by weighing
the substrate for nonenzymatic glycosylation of tissuethe overnight bag daily. Infusion pain and handling were evalu-
proteins [2, 3]. Furthermore, during heat sterilization,ated using a questionnaire. Peritoneal mesothelial and intersti-
tial integrity were evaluated by analyzing overnight effluent some of the glucose in conventional solutions is affected
dialysate concentrations of CA 125, hyaluronan (HA), pro- by the added heat and converted to fructose through
collagen-1-C-terminal peptide (PICP), and procollagen-3-N- isomerization and degraded to biologically reactive sub-terminal peptide (PIIINP) at 1, 6, 12, 18, and 24 months.
stances [4–7]. Chemically identified glucose degradationResults. The handling of the new two-compartment bag was
products (GDPs) commonly found in PD fluids are methyl-considered easy, and there were no indications of increased
discomfort with the new system. Furthermore, no changes in glyoxal, glyoxal, formaldehyde, 3-deoxyglucosone (3-DG),
peritoneal fluid or solute transport characteristics were ob- acetaldehyde, 2-furaldehyde, and 5-hydroxymethyl-fur-
served during the study period for either fluid, and neither aldehyde [6, 7].were there any differences with regard to peritonitis incidence.
These substances have been demonstrated to inhibitHowever, significantly higher dialysate CA 125 (73 6 41 vs.
cell proliferation and to cause necrosis of fibroblasts,25 6 18 U/mL), PICP (387 6 163 vs. 244 6 81 ng/mL), and
PIIINP (50 6 24 vs. 29 6 13 ng/mL) and significantly lower macrophages, and human mesothelial cells in vitro [8–13].
concentrations of HA (395 6 185 vs. 530 6 298 ng/mL) were There are indeed indications that GDPs, by causing pro-
tein denaturation or cross-linking, are basically cytotoxic
[14]. More specific detrimental effects of GDP in PDKey words: peritonitis, interstitial damage, dialysate solutions, biocom-
patible PD solution. fluids in vitro include impairment of cytokine release
and superoxide radical generation by peritoneal macro-Received for publication December 6, 1999
phages and by blood mononuclear and polymorphonu-and in revised form July 10, 2000
Accepted for publication July 25, 2000 clear cells [9, 15]. In animal models, GDPs also seem to
cause impairment of leukocyte rolling and an increasedÓ 2001 by the International Society of Nephrology
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venular flow velocity [16], even though in acute rat exper- fluids are demonstrated in Table 1. To ensure a balanced
composition of the patient material in each group, aiments no negative effects of GDP were observed with
respect to peritoneal solute transport or ultrafiltration stratified randomization was performed with respect to
patient age (,55, .55 years), diabetes (using insulin or(UF) [17]. Clinical studies indicate that GDP, at least in
combination with a low solution pH, may bring about not), and time on PD (,9 months, .9 months; Table 2).
Initially, the investigation was intended as a one-yearinfusion pain and impaired UF capacity [18, 19].
It has been demonstrated that GDPs are very potent clinical study, but it was later prolonged to include a
study period of two years, without adding any new pa-agents of nonenzymatic cross-linking of proteins, leading
to the formation of advanced glycation end products tients.
(AGEs). In particular, dicarbonyl compounds such as
Study population3-DG and methylglyoxal participate in these reactions
[7, 20–22]. A recent report has demonstrated extremely Patients were recruited if they were at least 18 years
old, gave their fully informed consent, and were able tohigh concentrations of 3-DG in conventional PD fluids
[7]. The role of GDP in AGE formation is of great rele- use 2 L bags with a calcium concentration of 1.35 mmol/L.
Patients were excluded from the study if they had avance, since AGEs are considered to participate in the
remodeling and fibrosis of the peritoneal membrane that positive screen for hepatitis B or HIV, or had an active
malignancy or were pregnant. Most of the patients (58%)may occur during long-term continuous ambulatory peri-
toneal dialysis (CAPD) treatment and that may be linked previously had not been treated on CAPD. Once found
eligible, patients were reported to a central randomiza-to an increased risk of UF failure [23, 24].
To avoid the generation of GDP, the PD fluid may tion office (at Gambro, Lund, Sweden) and were as-
signed to one of the two groups or strata (according tobe sterilized by filtration instead of being autoclaved.
Some generation of GDP will still occur during storage, age, diabetes, and time on PD) using a premade random-
ization schedule. The mean age at entry was 57 yearshowever. Another way to avoid the generation of GDP
is to dispense the fluid into a two-compartment bag, where for the control group and 58 years for the study group.
Diabetic patients represented 43% of the control groupconcentrated glucose is kept at a low pH (in a small com-
partment), separate from the electrolyte-buffer solution and 35% of the study group, respectively (Table 2).
(in a larger compartment). When this system is subjected
Study procedureto conventional heat sterilization and subsequent stor-
age, the generation of GDP will be very limited. Before Patients attended the participating hospital on five
occasions during the study period, that is, at 1, 6, 12, 18,use, the two compartments, however, have to be mixed.
This is the concept of the test solution in the present and 24 months after inclusion. Study parameters were
sampled within two weeks from the scheduled point ofstudy. Toxicological and chemical analyses of a fluid
produced and delivered in this way revealed that, besides time. Sampling did not take place within an episode of
peritonitis, but was postponed for four weeks after fullhaving a pH close to neutral, it showed very low levels
of GDP, essentially below the detection limit for 3-DG, recovery from peritoneal infection.
formaldehyde, and acetaldehyde [25]. With this composi-
Assessment of peritoneal membranetion, the solution’s in vitro cytotoxicity as well as its
exchange characteristicsability to induce AGE formation was clearly reduced
[3, 25]. The aim of our current study was to investigate Personal Dialysis Capacity (PDCe) was used as a tool
to assess the peritoneal transport characteristics [26].the long-term impact of this new fluid of PD on perito-
neal solute and fluid transport characteristics, as well The PDC procedure involves urine, blood, and dialysate
sampling during a standardized CAPD day carried outas on some tentative markers of peritoneal membrane
integrity. according to a special exchange schedule. The program
is based on the three-pore model of peritoneal transport
[27, 28] and describes peritoneal exchange using the fol-
METHODS
lowing parameters: (1) area parameter (A0/Dx), determin-
Study description ing the diffusion capacity of small solutes, and indirectly,
the hydraulic conductance of the membrane (LpS); (2)The study had a prospective, randomized, parallel de-
sign, including 80 patients randomly assigned to either the reabsorption rate of fluid from the peritoneal cavity
to the blood after peak time, when the glucose gradientGambrosol 40 CAPD solution [control group (C); N 5
40] or to the new, differently produced and nearly neutral has largely dissipated (JvAR); and (3) the large pore fluid
flow (JvL), which determines the loss of proteins to thefluid that was low in GDP [study group (S); N 5 40].
Both groups were using the Gemini 10 design (with drain PD fluid. Residual renal function (RRF) was also evalu-
ated in the PDC procedure and standardized to standardbag) or a slight modification thereof. The concentrations
of GDP, pH, and the in vitro cytotoxicity of the different body surface area (1.73 m2).
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Table 1. Chemical and biological characteristics of the two different fluids tested in the clinical study
Control group Study group
One compartment Two compartments
Characteristics
(contents of fluid bag) 1.5% 4% 1.5% 4%
pH 5.4360.01 5.3060.01 6.4360.01 6.2660.01
Cytotoxicity % 52.760.3 75.360.3 3.061.5 20.761.2
UV-abs 228 nm 0.5260.00 0.8360.02 0.1360.00 0.2860.03
UV-abs 284 nm 0.2060.00 0.4960.01 0.1960.00 0.4860.03
Acetaldehyde lmol/L 22665 26462 ,1 160
Formaldehyde lmol/L 4.660.1 9.160.4 ,1.7 ,1.7
Methylglyoxal lmol/L 22.760.5 33.361.4 ,2.8 ,2.8
Glyoxal lmol/L 5.560.3 7.560.1 5.860.3 6.660.3
5-HMF lmol/L 2.260.1 6.960.1 8.360.2 22.561.4
2-Furaldehyde lmol/L ,0.2 0.660.2 ,0.2 ,0.2
3-Deoxyglucosone 11865 413619 12.361.2 65610
Each sample represents the mean value from three separate bags 6 SEM. Data are transcribed from references 30 and 11. Abbreviations are: abs, absorption,
5-HMF, 5-hydroxymethyl-furaldehyde.
Table 2. Characteristics of the study patients or no?” then the degree of the pain sensation was as-
sessed by a nine-point visual analog scale (VAS).Characteristics Control group (N 5 40) Study group (N 5 40)
The breaking of the frangible pin and the mixing ofAge (years)a 57 (26–82) 58 (28–80)
Malesb 30 (75%) 25 (63%) the two compartments of the new bag were each evalu-
Diabeticsb 17 (43%) 14 (35%) ated by four grade scales using scores from 1 to 4 (1,
Time on CAPDc
simple; 4, difficult).0–9 months 34 35
.9 months 6 5
Participating centersa Mean age (range)
b Number of patients (percent) The patients were recruited from nine participating
c Number of patients in different categories (percent)
centers. The number of study patients (S) and control
patients (C) is given within parenthesis: University Hos-
pital of Lund (7 S; 8 C), Malmo¨ University Hospital (4 S;
3 C), Sahlgrenska University Hospital, Gothenburg (12 S;Ultrafiltration was evaluated during the study by daily
registration by the patient of the weight of the overnight 9 C), La¨nssjukhuset Halmstad (0 S; 1 C), Centralsjukhuset
Karlstad (1 S; 3 C), Centrallasarettet Bora˚s (2 S; 1 C),bag using an electronic scale. The concentration of glu-
cose in the night bag was 2.5%. Time for start and end Huddinge Hospital, Stockholm (3 S; 6 C; all in Sweden),
Rigshospitalet Copenhagen (4 S; 1 C), Hvidovre Hospi-of the overnight dwell was recorded, and the dwell time
was set at 10 hours. tal, Copenhagen (7 S; 8 C; in Denmark). The study proto-
col was approved by the ethics committee of each partici-
Dialysate markers pating center.
Samples of spent dialysate from the overnight bag were
Statistical analysiscollected and stored without any further treatment and
frozen at 2708C for later analysis. Analysis was performed Values are presented as box plots in the figures, with
the largest and smallest observed values (if not an outlierusing commercially available kits for CA 125 [enzyme-
linked immunosorbent assay (ELISA); Boehringer Mann- or extreme) as bars on the top or at the bottom of the
box. The median value is indicated within the box, eachheim, Mannheim, Germany], hyaluronan (HA; RIA;
Pharmacia, Uppsala, Sweden), procollagen-1-C-terminal box including 50% of the values. Values of more than
1.5 box lengths from the 25th percentile are presentedpeptide (PICP). and procollagen-3-N-terminal peptide
(PIINP; RIA from Orion Diagnostics, Espoo, Finland). as outliers (o), and values of more than 3 box lengths
from the 25th percentile, are presented as extremes (*).A separate study showed that the level of CA 125 was
unaffected by not subjecting the PD fluid to centrifugation The dropout rate as well as the peritonitis incidence
(with respect to first episode only) in each treatmentbefore freezing and storage (unpublished observation).
group was compared by the log rank test [29]. In addition,
Assessment of infusion pain and handling the Mann–Whitney test was employed to compare the
distribution of the patient-specific numbers of peritonitisThe patients completed a questionnaire covering sub-
jective symptoms in connection with infusion of the PD episodes during the one-year follow-up. Peritonitis inci-
dence, with respect to all episodes, was calculated andsolution. If the answer was yes on the first question of
“Do you feel any discomfort or pain during infusion, yes compared according to Rothman [30]. Infusion pain was
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Table 3. Distribution of the patients with respect to number of
peritonitis episodes
Control group Study group
Number of episodes (N 5 40) (N 5 40)
0 26 27
1 12 8
2 1 1
3 1 1
4 0 3
7 dropped out within the first month (4 in the control
group and 3 in the study group), and 16 chose (for per-
sonal reasons) not to continue a second year. Fifty-two
patients completed the first year, and 13 patients com-
pleted both years in the study, which represents a drop-
out rate during the first year of 35% (including the 7
patients who dropped out at the very start) and a dropout
rate during the second year of 64% (75%, including the
16 patients who chose not to continue a second year).
Except for the 7 initial dropouts and the 16 patients who
for various reasons decided not to continue the study,Fig. 1. Proportion of patients in the study over time, illustrating the
dropout rate. There was no significant difference between the group- the major dropout causes were transfer to hemodialysis
specific functions (P 5 0.25; log-rank test). The darker line is the study (N 5 6), transfer to automatic peritoneal dialysis (APD)
group and the lighter line is the control group.
or 2.5 L bags (N 5 8), transplantation (N 5 9), death
(N 5 7), or various other reasons (N 5 14). No significant
difference was observed in the dropout frequency be-
compared between the treatment groups using Fisher’s tween the control group or the study group (P 5 0.25;
exact test as well as the Mann–Whitney test. log-rank test).
From the daily assessments of the weight of the over-
Peritonitisnight bags, mean values were calculated for each subject
for defined time intervals. The “initial” mean was based Table 3 demonstrates the distribution of patients with
on data from weeks two through five of the study period, respect to number of peritonitis episodes. No significant
and the following mean values were based on data col- difference with respect to number of episodes or time
lected during each of the following consecutive five-week to the first peritonitis was observed (P 5 0.9 and P 5
periods. Subgroup analyses were performed with respect 0.35, respectively). The peritonitis incidences were 17
to diabetes and time on PD before inclusion (0 vs. .0 out of 36.41 years (0.467 per year) and 25 out of 45.07
month). The Kruskal–Wallis test was used to compare years (0.555 per year) in control and study groups, re-
treatment subgroups. The Mann–Whitney test was used spectively (P 5 0.6). Total peritonitis incidence for the
to compare overnight drained weights, area parameters, study was 1 out of 23.5 months.
and dialysate markers for the treatment groups with re-
Peritoneal transport characteristicsspect to initial values and (patient specific) changes dur-
ing the study. A P value of less than 0.05 is referred to In Figure 2, the normalized “unrestricted pore area
as significant. Bonferroni’s correction was applied when- over unit diffusion path length” (“area parameter” for
ever multiple comparisons were performed, and the P small solute transport; A0/Dx) is shown as a function
value obtained was less than 0.05. Exact P values were of study time in each group. There were no significant
calculated (StatXact 3; Cytel Software Corporation, differences among control and study groups initially
Cambridge, MA, USA) in situations in which the num- (after 1 month) nor in assessments at months 6, 12, 18,
bers of observations were small. All P values reported and 24, respectively. This also holds true for the hydraulic
are two tailed. conductance (LpS), the final reabsorption rate (JvAR),
the large pore fluid flux (JvL), and the renal residual
function (data not shown).RESULTS
Dropout rates Overnight bag weight
The overnight bag weight, assessed as a function ofThe dropout rate in the study is demonstrated in Fig-
ure 1. Out of the 80 patients randomized to the study, treatment time in each group, is shown for consecutive
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Fig. 2. Box plot of normalized (%) area pa-
rameter (A 0 /Dx) as a function of treatment
time in the (A) control group and (B) study
group. Each box includes 50% of all measured
values, with the largest and smallest observed
value as bars on the box top or at the box
bottom and the median value indicated within
the box. Values of more than 1.5 box lengths
from the 25th percentile are presented as out-
liers (o), and values of more than three box
lengths from the 25th percentile are presented
as extremes (*). N is the number of patients.
There were no significant differences among
study and control groups at any time with
respect to A 0 /Dx.
five-week periods in Figure 3. There were no significant cantly higher in the study group (P , 0.001), and HA
was significantly lower (P , 0.04). The use of individualdifferences whatsoever between the groups (P 5 0.21).
Moreover, the (patient specific) changes from the “ini- mean values was justified by the observation that the
patient-specific values did not change noticeably duringtial” value (mean value of weeks 2 through 5) to each
of the following five-week periods did not differ signifi- months 1 through 24.
cantly among the groups.
Infusion pain and handling
Dialysate markers The relative as well as the total number of patients
who experienced pain or discomfort during infusion de-Figures 4 and 5 demonstrate the levels of CA 125 and
HA among the two groups, respectively, at months 1, 6, creased from 31% (21 patients) at 1 month and 33% (19
patients) at 6 months to 13% (6 patients) at 12 months,12, 18, and 24. CA 125 levels were highly significantly
increased for the study group at all points of measure- to 13% (2 patients) at 18 months, and finally, to 20%
(2 patients) at 24 months. Since a sufficient number ofment, whereas HA showed significantly lower values
at month 12, and reductions that were of borderline patients reported pain at one and six months, these data
were chosen for further evaluation. At one month of thesignificance at months 1 and 18 (P 5 0.05). At 24 months
(and partly at 18 months), however, no powerful statisti- study, 40% (12 of 30) of the patients on conventional
fluid and 24% (9 of 37) of the patients on the new fluidcal analysis could be applied because of the low number
of patients. The levels of PICP and PIIINP were signifi- noted some kind of pain or discomfort. After six months,
these figures were 46% (11 of 24) and 24% (8 of 34),cantly higher in the test group at months 1, 6, 12, 18,
and 24. Thus, for PICP, P equaled 0.001 at 1 month, P , respectively. Although the new fluid tended to yield
fewer patients with discomfort or pain, this was not found0.001 at 6 months, P , 0.001 at 12 months, P 5 0.02 at
18 months, and P 5 0.9 at 24 months. For PIIINP, P to be statistically significant (P 5 0.19 and P 5 0.09,
respectively, using Fisher’s exact test for the dichoto-was 0.002 at 1 month, P , 0.001 at 6 months, P , 0.001
at 12 months, P 5 0.3 at 18 months, and P 5 0.07 at mous pain variable). For the patients reporting pain, no
significant differences were seen in the distribution of24 months. A power calculation demonstrated that a
minimum of 14 patients was needed in each group at the degree of pain using the nine-point scale rate (at 1
month P 5 0.12, at 6 months P 5 0.13, Mann–Whitneyany time to reveal a 20% significant difference (P ,
0.05; 80% power). test).
Evaluation of the study questionnaire indicated thatTo use all of the collected data in the statistical evalua-
tion, mean values for all the individual patient marker the handling of the new bag was easy. On a four-grade
scale with scores from 1 to 4 (1, simple; 4, difficult), thedata for months 1 through 24 were calculated and com-
pared (Table 4). CA 125, PICP, and PIIINP were signifi- new fluid scored a mean value (declining over time)
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Fig. 3. Box plots of drained weight in the overnight bag (2.5% glucose concentration) as a function of treatment time in the (A) control and (B)
study groups. N is the number of patients. A patient had a valid weekly observation, if at least one value was reported during each week. The
number of valid observations decreased more markedly in the control group than in the study group. No statistical difference among control and
study groups was obtained.
Fig. 4. Box plot of the concentration of CA
125 (U/mL) in overnight peritoneal effluent
for the (A) control and (B) study groups. The
study group showed significantly higher values
at all points of measurement (P , 0.001 at 1
month, P , 0.001 at 6 months, P 5 0.001 at
12 months, P 5 0.003 at 18 months, and P 5
0.007 at 24 months).
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Fig. 5. Box plot of the concentration of hya-
luronan (HA) (ng/mL) in overnight peritoneal
effluent for the (A) control and (B) study
groups. The study group showed lower (or
marginally lower) values at 1, 12, and 18
months. (P 5 0.05 at 1 month, P 5 0.6 at 6
months, P 5 0.04 at 12 months, P 5 0.05 at
18 months, and P 5 0.26 at 24 months). Over-
all, the HA concentration was lower in the
study group (Table 4).
Table 4. Dialysate concentration of CA 125, HA, that a new glucose-based solution of more or less identi-
PICP and PIIINP
cal composition as conventional ones, but having a near
Control group Study group neutral pH and being largely free of GDP, significantly
Dialysate marker N 5 34 N 5 36 affects some effluent markers of peritoneal membrane
CA 125 U/mL 25618 73641 integrity. Thus, CA 125, PICP, and PIIINP were found
HA ng/mL 5306298 3956185
to be significantly higher and HA lower with the newPICP ng/mL 244681 3876163
PIIINP ng/mL 29613 50624 fluid after one month and during up to 18 months of
treatment. However, there were no measurable effectsThe individual patient mean values for months 1 to 24 were calculated for
each treatment group. Data are shown as mean 6 SD. CA 125, PICP and PIIINP on peritoneal exchange parameters, including UF, with
values were higher in the study group (P , 0.001) and HA was lower (P , 0.04).
either the new or with the conventional control solution
during the two years of observation. A much longer
study period would have been required to reveal any
between 1.1 and 1.4 (frangible pin) and 1.0 to 1.2 (fluid changes in these parameters, since substantial increases
mixing). The study represents approximately 257 treat- in small solute (glucose) transport and reductions in UF
ment months and close to 65,000 exchanges with the new tend to first appear—if at all—after three or four years
bag. Thus, the handling of the new bag can be considered of treatment using conventional solutions [32].
easy and safe. Mesothelial cells lining the entire peritoneum produce
lubricants and surface tension-lowering substances, suchSubgroup analyses
as phospholipids, but also fibrinolytic and antithrombo-Subgroup analyses did not reveal any differences
genic substances, as well as cytokines and chemokines,among diabetics versus nondiabetics or among newly
and a number of other compounds, including HA, CArecruited patients versus patients who had been on PD
125, and collagen peptides [33, 34]. In this context, CApreviously with regard to any of the parameters discussed
125 and phospholipids can be regarded as more or lesspreviously in this article. Among the first-year dropouts,
specific for the mesothelium, whereas the other com-21 patients completed at least the first month of the
pounds also are produced by other cells in the perito-study, and of these, 13 belonged to the control group
neum. In fact, CA 125 effluent levels have been claimedand 8 to the study group. In neither group the dropouts
to reflect the mass of viable mesothelial cells in stablediffered significantly with respect to A0/Dx (transport PD patients [35–37]. During PD, the mesothelial cellstype) or CA 125 dialysate level from the non-dropouts
usually become cubic and multinucleate, tend to loseof the corresponding group.
their microvilli, and express more rough endoplasmatic
reticulum, at least over longer observation periods [38].
DISCUSSION The expression of more rough endoplasmatic reticulum
should, at least partly, reflect an increased mesothelialThe present study supports and extends the results of a
previous preliminary crossover study [31], demonstrating metabolic activity in response to the continuous loss of
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secretion products to the dialysate that occurs in PD rise in CA 125 may reflect a rapid regeneration of the
mesothelium during treatment with the new solution. Ac-[33]. Thus, the mesothelium is apparently “up-regulated”
to produce more secretion during CAPD in response to tually, ex vivo studies have recently demonstrated that
mesothelial cells (from the overnight effluent) grow tothe repeated exchanges of dialysate. Conceivably, up-
regulation of the mesothelium in this respect would be confluence in culture in a shorter time when harvested
from patients who have been on PD fluids with less GDPmore pronounced for a more physiological solution than
for a conventional one. Hence, the production of phos- than when harvested from patients previously exposed to
conventional solutions (abstract; Ja¨rkelid et al, Perit Dialpholipids, CA 125, collagen peptides, etc., can be ex-
pected to be higher with the new, more physiological Int 19:S54, 1999). These findings indicate that the mesothe-
lial cells seem more viable when exposed to the new fluid.PD fluid. On the other hand, inflammatory stimulation
of the mesothelium using proinflammatory cytokines has Hyaluronan is a major component of the interstitial
ground substance in most tissues. It is secreted into thenot been found to affect the release of CA 125 above
baseline levels, in contrast to the situation for HA (dis- peritoneal cavity by fibroblasts in the interstitium and
locally by the mesothelial cells [41]. HA is involved incussed later in this article) [35].
Mesothelial cells are frequently lost during the course several physiological processes, such as tissue repair and
remodeling, and also in primary morphogenesis [42]. Theof CAPD. Thus, along with an impaired remesotheliali-
zation, a frequent finding in long-term PD, partial meso- local HA production by tissue fibroblasts (and by the
mesothelium) increases very markedly, for example, dur-thelial denudation occurs [38]. Impaired survival of meso-
thelial cells might thus serve as an early indication of a ing peritonitis [41]. On the other hand, in edema states
or during conditions of high fluid flows through an unin-more or less severe peritoneal tissue damage or irritation,
eventually terminating in fibrosis. Such changes seem flamed interstitium, HA is easily washed out from the
tissue via the lymphatics [43]. The fraction of HA that isto occur during long-term treatment concomitant with
microvascular alterations, such as capillary neovasculari- produced by mesothelial cells forms a mesothelial surface
coat together with other glycosaminoglycans (GAGs) andzation, and possibly, increases in vascular permeability.
Compared with the capillary barrier, mesothelial cells and phospholipids [33, 42]. The continuous “rinsing” of the
peritoneal membrane by conventional PD solutions mostinterstitial tissue are, however, unlikely to play an impor-
tant role in the peritoneal transport of fluid and solutes likely causes mesothelial HA production to increase
slightly, since the concentration of HA is known to be[2, 27, 28, 36, 39]. Thus, early mesothelial and interstitial
changes would not be reflected by alterations in peritoneal considerably lower in fluid obtained at the first washout
in patients entering CAPD [41]. However, the markedtransport parameters [36].
Longitudinal examination of the dialysate during the increases in HA production by both fibroblasts and
mesothelial cells that occurs in peritonitis reflect in-course of CAPD, in accordance with the morphological
changes, has demonstrated declining CA 125 dialysate flammatory stimulation. In fact, HA seems to act as a
peripheral inflammation marker [42]. In this perspective,levels with increasing treatment time [37]. Our results of
higher dialysate CA 125 levels during the use of the new the lower HA production in the test group is consistent
with a more physiological situation for the new solution.fluid strongly indicate that the mesothelial cells are not
as negatively affected throughout the treatment as by con- Procollagen-1-C-terminal peptide and PIIINP are re-
leased during the synthesis of collagen I and collagen III,ventional PD fluids. Elevations of dialysate in CA 125
were observed early, that is, after a treatment period of respectively, and are used as markers for overall collagen
synthesis [33, 34, 44]. Dialysate concentrations reflectonly one month [40], which was similar to observations
in our previous cross-over study [31]. Here, significant locally produced PICP and PIIINP by fibroblasts and
mesothelial cells [33, 44]. Our results of a higher concen-increases in CA 125 were observed as soon as 6 and 12
weeks of treatment for a solution largely free of GDP. tration of PICP and PIIINP for the new fluid most proba-
bly reflect an improved cell function of the mesotheliumFurthermore, the CA 125 levels again dropped to low
values after switching the patients back to conventional and thus more collagen release to the effluent. The data
may, of course, also indicate an ongoing fibrosis with adialysis fluids [31, 40]. Whether these changes reflect alter-
ations of the mesothelial cell mass, or alternatively, were higher collagen turnover. In this context, however, it is
noticeable that Graff et al did not show a correlationdue to changes in CA 125 production per cell is not known.
One should keep in mind that approximately 40% of our between the production of collagen peptides and long-
term CAPD or peritonitis incidence, conditions thatpatients had been previously exposed to conventional PD
fluids. This group of patients also showed an elevation of would be expected to be associated with more peritoneal
fibrosis [44].CA 125 during treatment with the new fluid; that is, they
did not differ from the group of patients who had never The mechanism by which GDP alone or in combina-
tion with high glucose concentrations (and other toxicbeen exposed to PD fluids before. Thus, if mesothelial
cell mass is positively influenced by the new fluid, the influences) affects the mesothelial cells remains to be
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Hospital Gothenburg, Sweden), and Christina Landgren, Christinaelucidated. One possibility is that there is a direct toxic
Scho¨nborg, Anette Larsen, Helen Andersson, Annika Larsson, Helle
action of GDP through carbonyl-induced cross-linking Larsson, Thierry Crost, Eva Svensson, Lena Ja¨rkelid, Per Kjellstrand,
of surface proteins and of intracellular proteins or nucleic Mary-Ann Ernstsson, and Lena Olsson (Gambro AB). We also thank
Ulf Stro¨mberg for statistical analysis and Kerstin Wihlborg for skillfulacids. For instance, formaldehyde, a well-known fixative,
typing of the manuscript.easily penetrates the cell membrane and immediately
cross-links several intracellular components. Further- Reprint requests to Dr. Bengt Rippe, Department of Nephrology,
University Hospital of Lund, S-221 85 Lund, Sweden.more, GDP can promote AGE formation in an environ-
E-mail: Bengt.Rippe@njur.lu.sement of high glucose levels, which is of great relevance
since AGE seem to reduce the viability of mesothelial
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